WO2008065142A1 - Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative - Google Patents
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative Download PDFInfo
- Publication number
- WO2008065142A1 WO2008065142A1 PCT/EP2007/062958 EP2007062958W WO2008065142A1 WO 2008065142 A1 WO2008065142 A1 WO 2008065142A1 EP 2007062958 W EP2007062958 W EP 2007062958W WO 2008065142 A1 WO2008065142 A1 WO 2008065142A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- rocuronium
- pharmaceutical composition
- solution
- cyclodextrin derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to a pharmaceutical composition in the form of an aqueous solution for parenteral administration comprising rocuronium and a derivative of ⁇ -cyclodextrin.
- Rocuronium is a neuromuscular blocking agent.
- a neuromuscular blocking agent is routinely used during the administration of anaesthesia to facilitate endotracheal intubation and to allow surgical access to body cavities, in particular the abdomen and thorax, without hindrance from voluntary or reflex muscle movement.
- Neuromuscular blocking agents are also used in the care of critically-ill patients undergoing intensive therapy, to facilitate compliance with mechanical ventilation when sedation and analgesia alone have proved inadequate.
- Rocuronium 1-[(2 ⁇ , 3 ⁇ , 5 ⁇ , 16 ⁇ , 17 ⁇ )-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)- androstan-16-yl]-1-(2-propenyl)pyrrolidinium (US 4,894,369, Akzo Nobel N.V.), is a steroidal neuromuscular blocking agent which is marketed as its bromide using the tradenames Esmeron® and Zemuron®.
- the market product is a 10 mg/ml solution of rocuronium bromide in an aqueous acetate buffer of pH 4.0, which is to be stored at 2-8 0 C in order to attain a sufficient shelf-life.
- an aqueous pharmaceutical composition of rocuronium which can be stored at ambient temperature and/or at higher pH while maintaining an adequate shelf-life.
- This object is achieved by providing an aqueous solution comprising in addition to rocuronium a sulfoalkylether- ⁇ -cyclodextrin derivative or a pharmaceutically acceptable salt thereof.
- ⁇ -Cyclodextrin is a cyclic oligosaccharide containing seven ⁇ -(1-4)-linked D- glucopyranose units.
- sulfoalkylether- ⁇ -cyclodextrin derivative means ⁇ -cyclodextrin which has been derivatised at one or more of its 2-, 3- and 6-hydroxyl functions to introduce an anionic (C 2 -6alkylene)-SO 3 " substituent.
- anionic (C 2 -6alkylene)-SO 3 " substituent Such derivatives are disclosed in US Patent 5,134,127 (University of Kansas).
- a sulfoalkylether- ⁇ -cyclodextrin derivative may either be a single well defined derivative or may be a mixture of derivatives obtained by random derivatisation of the ⁇ -cyclodextrin hydroxyl functions with a certain molecular excess of an alkylating reagent, such as for example an (C 2-6 alkyl)sultone in the presence of a base, for instance by procedures described in US 6,153,746 (Pfizer Inc).
- an alkylating reagent such as for example an (C 2-6 alkyl)sultone in the presence of a base, for instance by procedures described in US 6,153,746 (Pfizer Inc).
- Such randomly derivatised sulfoalkylether- ⁇ -cyclodextrin derivatives are characterized by a degree of substitution, meaning the average number of derivatised hydroxyl groups per molecule.
- the degree of substitution may range from about 1 to about 8 sulfoalkylether groups per ⁇ -cyclodextrin.
- Preferred sulfoalkylether- ⁇ -cyclodextrin derivatives for use in the invention are the sulfobutylether- ⁇ -cyclodextrin derivatives.
- the invention comprises a sulfobutylether- ⁇ - cyclodextrin having an average of about 7 sulfobutylether substituents per cyclodextrin molecule (annotated as: sulfobutylether 7- ⁇ -cyclodextrin).
- Sulfobutylether 7- ⁇ -cyclodextrin has been commercialized by CyDex, Inc. as Captisol® and Advasep 7 ®, and with an average of about 4 substituents as Advasep 4 ®.
- the pharmaceutical composition according to the invention preferably comprises rocuronium as the bromide salt in a concentration in the range of 0.2 to 2.5% m/v.
- a preferred concentration of rocuronium bromide is 0.5 to 1.5% m/v.
- the pharmaceutical composition of the invention preferably comprises from 1 to 40% m/v of the sulfoalkylether- ⁇ -cyclodextrin derivative, more preferably from 5 to 15% m/v of the sulfoalkylether- ⁇ -cyclodextrin derivative.
- a preferred pharmaceutical composition of the invention for parenteral administration is an aqueous solution containing about 1 % m/v rocuronium bromide and about 10% m/v of sulfobutylether 7- ⁇ -cyclodextrin.
- the pharmaceutical composition is preferably isotonic and may comprise a buffer.
- the buffer is selected from the group consisting of a phosphate buffer, a phosphate/citrate buffer, a citrate buffer.
- the buffer is a phosphate/citrate buffer.
- the pH of the pharmaceutical composition according to the invention may be anywhere in the range of 3.5 to 7.5.
- the pH is in the range of 5.5 to 7.5.
- citrate/phosphate buffers with a pH of 5.0 and 6.0 (buffers prepared by applying a 1 OmM citrate and a 2OmM phosphate solution):
- A1 rocuronium bromide (1 mg/ml) (comparative example; reference solution);
- A2 rocuronium bromide (1 mg/ml) and 2-hydroxypropyl- ⁇ -cyclodextrin (10mg/ml)
- the solutions were stored at 40 0 C for a period of 3 months in closed containers and subsequently analyzed by means of HPLC.
- A4 rocuronium bromide (1 mg/ml) (comparative example; reference solution);
- A5 rocuronium bromide (1 mg/ml) and 2-hydroxypropyl- ⁇ -cyclodextrin (approx. 8 mg/ml) (comparative example);
- A6 rocuronium bromide (1 mg/ml) and sulfobutylether 7- ⁇ -cyclodextrin (Captisol®)
- the solutions were stored at 22-24 ° C for a period of 44 hours and subsequently analyzed by means of HPLC.
- citrate/phosphate buffer with a pH of 7.0 (buffer prepared by mixing a 0.1 M citrate and a 0.2 M phosphate solution):
- A7 rocuronium bromide (1 mg/ml)(comparative example; buffer solution pH 7.0);
- A8 rocuronium bromide(1 mg/ml) and ⁇ -cyclodextrin (10mg/ml)(comparative example);
- A10 rocuronium bromide(1 mg/ml) and ⁇ -cyclodextrin (10mg/ml)(comparative example);
- A1 1 rocuronium bromide(1 mg/ml) and sulfobutylether 4- ⁇ -cyclodextrin(Advasep 4 ®) (10mg/ml);
- A12 rocuronium bromide(1 mg/ml) and sulfobutylether 7- ⁇ -cyclodextrin (Captisol®) (10mg/ml).
- the solutions were treated by heat sterilization at 121 ° C for 1 hour in closed containers and subsequently analyzed by means of HPLC.
Landscapes
- Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a pharmaceutical composition in the form of an aqueous solution for parenteral administration comprising rocuronium and a sulfoalkylether-ß-cyclodextrin derivative or a pharmaceutically acceptable salt thereof.
Description
STABILIZED SOLUTION OF ROCURONIUM COMPRISING A SULFOALKYL-ETHER-BETA-CYCLODEXTRIN DERIVATIVE
The present invention relates to a pharmaceutical composition in the form of an aqueous solution for parenteral administration comprising rocuronium and a derivative of β-cyclodextrin.
Rocuronium is a neuromuscular blocking agent. A neuromuscular blocking agent is routinely used during the administration of anaesthesia to facilitate endotracheal intubation and to allow surgical access to body cavities, in particular the abdomen and thorax, without hindrance from voluntary or reflex muscle movement. Neuromuscular blocking agents are also used in the care of critically-ill patients undergoing intensive therapy, to facilitate compliance with mechanical ventilation when sedation and analgesia alone have proved inadequate.
Rocuronium, 1-[(2β, 3α, 5α, 16β, 17β)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)- androstan-16-yl]-1-(2-propenyl)pyrrolidinium (US 4,894,369, Akzo Nobel N.V.), is a steroidal neuromuscular blocking agent which is marketed as its bromide using the tradenames Esmeron® and Zemuron®. The market product is a 10 mg/ml solution of rocuronium bromide in an aqueous acetate buffer of pH 4.0, which is to be stored at 2-8 0C in order to attain a sufficient shelf-life. There is a need for an aqueous pharmaceutical composition of rocuronium which can be stored at ambient temperature and/or at higher pH while maintaining an adequate shelf-life.
Cyclodextrins and their pharmaceutical applications have been reviewed by Stella and Rajewski (Pharmaceutical Research, 14, 556-567, 1997). The effects on solubility and stability of the addition of cyclodextrins or cyclodextrin derivatives to aqueous solutions of steroid hormones have been described in the art. In Journal of Pharmaceutical Sciences (1992), 81.(8), 756-61 , Albers, E. and Mϋller B. W. disclose a reduction in the rate of degradation of steroid esters by inclusion of 2-hydroxypropyl-β-cyclodextrin. Loftsson T. et al, International Journal of Pharmaceutics (1993), 98(1-3), 225-30, describe the stabilizing effects of 2-hydroxypropyl-β- cyclodextrin, reducing the degradation of medroxyprogesteron acetate and megestrol acetate in buffered solutions 2.5 to 4 times. In a review article on pharmaceutical applications of cyclodextrins by Loftsson and Brewster (J. Pharm. Sci. 85, 1017- 1025, 1996) it is emphasized that cyclodextrin interactions with labile drug molecules can either have stabilizing or destabilizing effects, depending on the particular combination of drug and cyclodextrin.
It is the object of the present invention to provide a pharmaceutical composition comprising rocuronium in the form of an aqueous solution for parenteral administration which has a pH and/or a storage temperature range which allows easy manufacture and storage.
This object is achieved by providing an aqueous solution comprising in addition to rocuronium a sulfoalkylether-β-cyclodextrin derivative or a pharmaceutically acceptable salt thereof.
β-Cyclodextrin is a cyclic oligosaccharide containing seven α-(1-4)-linked D- glucopyranose units.
The term sulfoalkylether-β-cyclodextrin derivative means β-cyclodextrin which has been derivatised at one or more of its 2-, 3- and 6-hydroxyl functions to introduce an anionic (C2-6alkylene)-SO3 " substituent. Such derivatives are disclosed in US Patent 5,134,127 (University of Kansas). A sulfoalkylether-β-cyclodextrin derivative may either be a single well defined derivative or may be a mixture of derivatives obtained by random derivatisation of the β-cyclodextrin hydroxyl functions with a certain molecular excess of an alkylating reagent, such as for example an (C2-6alkyl)sultone in the presence of a base, for instance by procedures described in US 6,153,746 (Pfizer Inc).
Such randomly derivatised sulfoalkylether-β-cyclodextrin derivatives are characterized by a degree of substitution, meaning the average number of derivatised hydroxyl groups per molecule. The degree of substitution may range from about 1 to about 8 sulfoalkylether groups per β-cyclodextrin.
Preferred sulfoalkylether-β-cyclodextrin derivatives for use in the invention are the sulfobutylether-β-cyclodextrin derivatives.
In a further preferred embodiment the invention comprises a sulfobutylether-β- cyclodextrin having an average of about 7 sulfobutylether substituents per cyclodextrin molecule (annotated as: sulfobutylether 7-β-cyclodextrin). Sulfobutylether 7-β-cyclodextrin has been commercialized by CyDex, Inc. as Captisol® and Advasep 7 ®, and with an average of about 4 substituents as Advasep 4 ®.
The pharmaceutical composition according to the invention preferably comprises rocuronium as the bromide salt in a concentration in the range of 0.2 to 2.5% m/v. A preferred concentration of rocuronium bromide is 0.5 to 1.5% m/v.
The pharmaceutical composition of the invention preferably comprises from 1 to 40% m/v of the sulfoalkylether-β-cyclodextrin derivative, more preferably from 5 to 15% m/v of the sulfoalkylether-β-cyclodextrin derivative.
A preferred pharmaceutical composition of the invention for parenteral administration is an aqueous solution containing about 1 % m/v rocuronium bromide and about 10% m/v of sulfobutylether 7-β-cyclodextrin.
The pharmaceutical composition is preferably isotonic and may comprise a buffer. The buffer is selected from the group consisting of a phosphate buffer, a phosphate/citrate buffer, a citrate buffer. Preferably the buffer is a phosphate/citrate buffer.
The pH of the pharmaceutical composition according to the invention may be anywhere in the range of 3.5 to 7.5. For convenience in terms of low incidence of pain induction on injection, it is preferable that the pH is in the range of 5.5 to 7.5.
The invention is illustrated in the following Examples:
Example 1
The following solutions were prepared in citrate/phosphate buffers with a pH of 5.0 and 6.0 (buffers prepared by applying a 1 OmM citrate and a 2OmM phosphate solution):
A1 : rocuronium bromide (1 mg/ml) (comparative example; reference solution); A2: rocuronium bromide (1 mg/ml) and 2-hydroxypropyl-β-cyclodextrin (10mg/ml)
(comparative example); A3: rocuronium bromide (1 mg/ml) and sulfobutylether 7-β-cyclodextrin (Captisol®)
(10mg/ml).
The solutions were stored at 40 0C for a period of 3 months in closed containers and subsequently analyzed by means of HPLC.
The contents of rocuronium bromide after storage expressed as percentage of the initial content are reflected in Table 1.
Table 1 : Content of rocuronium bromide (%) after storage
The solution of rocuronium bromide comprising 2-hydroxypropyl-β-cyclodextrin (Table 1 : A2) shows that a slight to no reduction of the degradation of rocuronium as compared to the reference solution A1 at both pH 5 and 6.
The chemical stability of rocurinium bromide in a solution according to the invention comprising sulfobutylether 7-β-cyclodextrin is significantly improved during storage at 40° C, both a pH 5 and 6 (Table 1 : A3).
Example 2
The following solutions with pH 10 were prepared in a buffer system (25 mM phosphate buffer pH 7.1 brought to pH with a 10% ammonium hydroxide solution):
A4: rocuronium bromide (1 mg/ml) (comparative example; reference solution); A5: rocuronium bromide (1 mg/ml) and 2-hydroxypropyl-β-cyclodextrin (approx. 8 mg/ml) (comparative example); A6: rocuronium bromide (1 mg/ml) and sulfobutylether 7-β-cyclodextrin (Captisol®)
(approx. 8 mg/ml).
The solutions were stored at 22-24 °C for a period of 44 hours and subsequently analyzed by means of HPLC.
The percentage of rocuronium bromide recovered after storage expressed as percentage of the initial content are reflected in Figure 1.
The results show that for the solution buffered at pH 10 no significant improvement of the stability of rocuronium bromide was obtained by 2-hydroxypropyl-β-cyclodextrin (Figure 1 : A5), whereas at this high pH sulfobutyl ether 7-β-cyclodextrin (Captisol®) significantly improved the stability of rocuronium bromide (Figure 1 : A6).
Example 3
The following solutions were prepared in citrate/phosphate buffer with a pH of 7.0 (buffer prepared by mixing a 0.1 M citrate and a 0.2 M phosphate solution):
A7: rocuronium bromide (1 mg/ml)(comparative example; buffer solution pH 7.0); A8: rocuronium bromide(1 mg/ml) and α-cyclodextrin (10mg/ml)(comparative example);
A9: rocuronium bromide(1 mg/ml) and β-cyclodextrin (10mg/ml))(comparative example);
A10: rocuronium bromide(1 mg/ml) and γ-cyclodextrin (10mg/ml)(comparative example);
A1 1 : rocuronium bromide(1 mg/ml) and sulfobutylether 4-β-cyclodextrin(Advasep 4 ®) (10mg/ml); A12: rocuronium bromide(1 mg/ml) and sulfobutylether 7-β-cyclodextrin (Captisol®) (10mg/ml).
The solutions were treated by heat sterilization at 121 °C for 1 hour in closed containers and subsequently analyzed by means of HPLC.
The contents of rocuronium bromide after storage expressed as percentage of the initial content are reflected in Table 2.
Table 2: Recovery of rocuronium bromide (%) after storage at pH 7.0.
The chemical stability of rocuronium bromide upon heat sterilization at 121 °C for 1 hour in a solution according to the invention (A11 and A12) is significantly improved (Table 2).
Claims
1. A pharmaceutical composition in the form of an aqueous solution for parenteral administration comprising rocuronium, characterized in that the solution further comprises a sulfoalkylether-β-cyclodextrin derivative or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition according to claim 1 , wherein the sulfoalkylether-β- cyclodextrin derivative is a sulfobutylether-β-cyclodextrin derivative.
3. A pharmaceutical composition according to claim 2, wherein the sulfobutylether-β- cyclodextrin derivative is sulfobutylether 7-β-cyclodextrin.
4. A pharmaceutical composition according to any one of claims 1-3, wherein the solution comprises a phosphate/citrate buffer.
5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the pH of solution is in the range of 3.5 to 7.5.
6. A pharmaceutical composition according to any one of claims 1 to 5, wherein rocuronium is rocuronium bromide.
7. A pharmaceutical composition according to claim 6, wherein the concentration of rocuronium bromide is in the range of is 0.2 to 2.5% m/v.
8. A pharmaceutical composition according to any one of claims 1 to 7, wherein the concentration of the cyclodextrin is in the range of 1 to 40 % m/v.
9. A pharmaceutical composition according to any one of claims 1 to 7, wherein the concentration of the cyclodextrin is in the range of 5 to 15 % m/v.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125015 | 2006-11-29 | ||
EP06125015.5 | 2006-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008065142A1 true WO2008065142A1 (en) | 2008-06-05 |
Family
ID=37805942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/062958 WO2008065142A1 (en) | 2006-11-29 | 2007-11-28 | Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008065142A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013189800A1 (en) * | 2012-06-22 | 2013-12-27 | Farmhispania S.A. | Cisatracurium and beta-cyclodextrin derivative compositions |
EP2712611A1 (en) | 2012-09-27 | 2014-04-02 | B. Braun Melsungen AG | Stabilized aqueous compositions of neuromuscular blocking agents |
JP5684954B1 (en) * | 2014-06-26 | 2015-03-18 | 丸石製薬株式会社 | Rocuronium formulation with improved stability |
EP3017817A4 (en) * | 2013-07-01 | 2017-03-22 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation with improved vascular pain, method for producing same, and method for suppressing and relieving vascular pain using same |
ES2658115A1 (en) * | 2016-05-10 | 2018-03-08 | Farmhispania S.A. | Compositions of cisatracurium and beta-cyclodextrin derivatives. (Machine-translation by Google Translate, not legally binding) |
CN108289832A (en) * | 2015-11-06 | 2018-07-17 | 卡利努法姆股份有限公司 | For carrying out the Levosimendan of intravenously administrable with infusion or injection form and being transfused the improvement formula of concentrate |
US11097023B1 (en) | 2020-07-02 | 2021-08-24 | Par Pharmaceutical, Inc. | Pre-filled syringe containing sugammadex |
WO2023275157A1 (en) | 2021-07-02 | 2023-01-05 | Fresenius Kabi Austria Gmbh | Aqueous, room-temperature stable rocuronium composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011172A1 (en) * | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US6153746A (en) * | 1997-07-01 | 2000-11-28 | Pfizer Inc. | Process for making a cyclodextrin |
WO2005065649A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid |
-
2007
- 2007-11-28 WO PCT/EP2007/062958 patent/WO2008065142A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991011172A1 (en) * | 1990-01-23 | 1991-08-08 | The University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
US6153746A (en) * | 1997-07-01 | 2000-11-28 | Pfizer Inc. | Process for making a cyclodextrin |
WO2005065649A1 (en) * | 2003-12-31 | 2005-07-21 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether ϝ-cyclodextrin and corticosteroid |
Non-Patent Citations (3)
Title |
---|
GORECKA BARBARA A ET AL: "Effect of SBE4-beta-CD, a sulfobutyl ether beta-cyclodextrin, on the stability and solubility of O-6-benzylguanine (NSC-637037) in aqueous solutions", INTERNATIONAL JOURNAL OF PHARMACEUTICS (AMSTERDAM), vol. 125, no. 1, 1995, pages 55 - 61, XP002423709, ISSN: 0378-5173 * |
RAJEWSKI R A ET AL: "PRELIMINARY SAFETY EVALUATION OF PARENTERALLY ADMINISTERED SULFOALKYL ETHER -CYCLODEXTRIN DERIVATIVES", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 84, no. 8, 1 August 1995 (1995-08-01), pages 927 - 932, XP000517190, ISSN: 0022-3549 * |
STELLA VALENTINO J ET AL: "Cyclodextrins: Their Future in Drug Formulation and Delivery", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 14, no. 5, May 1997 (1997-05-01), pages 556 - 567, XP002080397, ISSN: 0724-8741 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013189800A1 (en) * | 2012-06-22 | 2013-12-27 | Farmhispania S.A. | Cisatracurium and beta-cyclodextrin derivative compositions |
EP2712611A1 (en) | 2012-09-27 | 2014-04-02 | B. Braun Melsungen AG | Stabilized aqueous compositions of neuromuscular blocking agents |
KR101803857B1 (en) | 2013-07-01 | 2017-12-04 | 마루이시세이야쿠가부시키가이샤 | Rocuronium preparation with improved vascular pain, method for producing same, and method for suppressing and relieving vascular pain using same |
US10821119B2 (en) | 2013-07-01 | 2020-11-03 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation causing less pain, method for producing the same, and method for reducing and/or alleviating vascular pain to be induced using the same |
AU2014285324B2 (en) * | 2013-07-01 | 2019-05-23 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation causing less pain, method for producing the same, and method for reducting and/or alleviating vascular pain to be induced using the same |
RU2680405C2 (en) * | 2013-07-01 | 2019-02-21 | Маруиси Фармасьютикал Ко., Лтд. | Rocuronium preparation with improved vascular pain, method for producing same, and method for suppressing and/or relieving vascular pain which may be caused by use thereof |
EP3017817A4 (en) * | 2013-07-01 | 2017-03-22 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation with improved vascular pain, method for producing same, and method for suppressing and relieving vascular pain using same |
AU2014398349B2 (en) * | 2014-06-26 | 2020-08-06 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation with improved stability |
KR101692884B1 (en) | 2014-06-26 | 2017-01-04 | 마루이시세이야쿠가부시키가이샤 | Rocuronium preparation with improved stability |
KR20160086953A (en) | 2014-06-26 | 2016-07-20 | 마루이시세이야쿠가부시키가이샤 | Rocuronium formulation with improved stability |
WO2015198456A1 (en) * | 2014-06-26 | 2015-12-30 | 丸石製薬株式会社 | Rocuronium formulation with improved stability |
JP5684954B1 (en) * | 2014-06-26 | 2015-03-18 | 丸石製薬株式会社 | Rocuronium formulation with improved stability |
US10869876B2 (en) | 2014-06-26 | 2020-12-22 | Maruishi Pharmaceutical Co., Ltd. | Rocuronium preparation with improved stability |
CN113350274A (en) * | 2014-06-26 | 2021-09-07 | 丸石制药株式会社 | Rocuronium bromide formulations with improved stability |
CN108289832A (en) * | 2015-11-06 | 2018-07-17 | 卡利努法姆股份有限公司 | For carrying out the Levosimendan of intravenously administrable with infusion or injection form and being transfused the improvement formula of concentrate |
ES2658115A1 (en) * | 2016-05-10 | 2018-03-08 | Farmhispania S.A. | Compositions of cisatracurium and beta-cyclodextrin derivatives. (Machine-translation by Google Translate, not legally binding) |
US11097023B1 (en) | 2020-07-02 | 2021-08-24 | Par Pharmaceutical, Inc. | Pre-filled syringe containing sugammadex |
WO2023275157A1 (en) | 2021-07-02 | 2023-01-05 | Fresenius Kabi Austria Gmbh | Aqueous, room-temperature stable rocuronium composition |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008065142A1 (en) | Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative | |
Jansook et al. | Cyclodextrins: structure, physicochemical properties and pharmaceutical applications | |
Kim et al. | Solubility enhancement and application of cyclodextrins in local drug delivery | |
Mosher et al. | Complexation and cyclodextrins | |
Loftsson et al. | Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes | |
JP4439596B2 (en) | Pharmaceutical composition containing polar drug or polar prodrug having long shelf life, and method for producing the same | |
EP2525798B1 (en) | Anaesthetic formulation | |
Cirri et al. | Simultaneous effect of cyclodextrin complexation, pH, and hydrophilic polymers on naproxen solubilization | |
WO2008005819A2 (en) | Ophthalmic formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | |
US20070020298A1 (en) | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | |
BRPI0418276B1 (en) | inhalable liquid formulation comprising budesonide | |
KR20170133315A (en) | Grafting of cyclodextrin by amide bonds to an ether cross-linked hyaluronic acid and uses thereof | |
EP1973524A1 (en) | Concentrated liquid thyroid hormone composition | |
CA2519418A1 (en) | New injectable formulations containing progesterone | |
JP2003063965A (en) | Cilostazol aqueous composition for injection | |
WO2005112883A1 (en) | Preserved pharmaceutical compositions comprising cyclodextrins | |
JP3597239B2 (en) | Stable eye drops | |
EP3556349A1 (en) | Parenteral liquid preparation comprising carbamate compound | |
Ramos-Martínez et al. | Use of cyclodextrins as excipients in pharmaceutical products: why not in extemporaneous preparations? | |
CA2237023C (en) | Improved formulation for administration of steroid compounds | |
WO2005102312A1 (en) | Concentrated oxaliplatin solutions | |
JP7526175B2 (en) | Cyclodextrin-Based Formulations of Bcl-2 Inhibitors - Patent application | |
JP2805539B2 (en) | Poly-γ-cyclodextrin inclusion compound | |
JPH07316065A (en) | Pharmaceutical preparation of fr 901469 substance | |
WO2002045721A1 (en) | Noble gas complexes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07847475 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07847475 Country of ref document: EP Kind code of ref document: A1 |